Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 21, 2026; 32(35): 120142
Published online Sep 21, 2026. doi: 10.3748/wjg.120142
Published online Sep 21, 2026. doi: 10.3748/wjg.120142
Letter to the Editor: Helicobacter pylori eradication in aspirin users - gastroprotection established, cardiovascular implications to be clarified
Yavuz Özden, Department of Gastroenterology, Kayseri City Hospital, University of Health Sciences, Kayseri 38080, Türkiye
Author contributions: Özden Y conceived and wrote this letter, and approved the final version to publish.
AI contribution statement: This manuscript did not use any artificial intelligence tool to generate its scientific content, interpretations, arguments, or conclusions. Artificial intelligence-assisted language tools were used only to a limited extent for language and fluency refinement. No artificial intelligence tool was used in the design of the study, interpretation of the literature, or data analysis. The author critically reviewed and approved the final version of the manuscript and takes full responsibility for its content.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Yavuz Özden, MD, Department of Gastroenterology, Kayseri City Hospital, University of Health Sciences, Şeker District, Muhsin Yazıcıoğlu Boulevard No. 77 Kocasinan, Kayseri 38080, Türkiye. yavuzozden@gmail.com
Received: February 27, 2026
Revised: March 10, 2026
Accepted: May 20, 2026
Published online: September 21, 2026
Processing time: 181 Days and 13 Hours
Revised: March 10, 2026
Accepted: May 20, 2026
Published online: September 21, 2026
Processing time: 181 Days and 13 Hours
Core Tip
Core Tip: Helicobacter pylori eradication in chronic aspirin users appears to provide meaningful gastrointestinal protection and may reduce peptic ulcer bleeding risk. However, the reported cardiovascular benefit should be interpreted cautiously because of short follow-up, composite endpoint selection, possible residual confounding, and modest eradication success. Future studies should focus on optimized eradication strategies and hard cardiovascular outcomes.